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ﬁrst two decades of infection
The high prevalence of hepatitis viruses C (HCV) and B (HBV) as
well as co-infection with human immune deﬁciency virus (HIV)
among intravenous drug users (IDUs) is by now common knowl-
edge [1,2]. Co-infection with HCV and HIV is reported to be asso-
ciated with lower rates of spontaneous HCV clearance, faster
progression of chronic liver disease to cirrhosis and lower
response rates to anti-HCV treatment [3,4]. Thus most, although
not all studies report an accelerated course of hepatic ﬁbrosis
in HIV/HCV co-infected patients [5–7]. In contrast to HCV-HIV
co-infection, the natural history of chronic HCV infection in the
relatively large population of HCV mono-infected (HIV negative)
IDU population receives much less attention. A literature search
revealed conﬂicting data regarding the long-term natural history
of chronic hepatitis C and progression of ﬁbrosis in HIV negative
IDUs [5–7]. In this context it should be mentioned that additional
risk factors except for HIV, i.e., overdose of opiates, excessive
alcohol intake, malnutrition and others may have an impact on
the natural history and survival of HCV infected IDUs. Up to date
epidemiologic data on prevalence and natural history of hepatitis
viruses in IDUs are mainly deducted from estimates and not from
accurate public health, molecular epidemiologic or clinical sur-
veillance data [8–11]. A recent systematic review published in
the Lancet summarized HCV prevalence data in IDUs from 77
countries [9]. According to this analysis (which the authors
acknowledge as an under-estimate) there are approximately 10
million anti-HCV positive IDUs worldwide, the majority living
in China (1.6 million), in the USA (1.5 million), and Russia
(1.3 million). Anti-HCV prevalence among IDUs ranged between
60–80% in 25 countries and above 80% in 12 countries. A similar
survey on the global epidemiology of HIV among IDUs was
reported in 2008 by the same group [8]. Prevalence estimates
from 61 countries containing 77% of the world’s total population,
aged 15–64 years, suggest that there are at least 15.9 millionJournal of Hepatology 20
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Open access under CC BY-NC-ND license.IDUs worldwide, mainly in China, the USA, and Russia. The mid
estimates of HIV prevalence in IDUs in these countries are 12%,
16%, and 37% respectively. The authors estimate that about 3 mil-
lion IDUs worldwide are HIV positive [8]. Based on these two
large surveys, and irrespective whether these are under-esti-
mates, it is clear that the global burden of HCV carriers among
IDUs far exceeds the numbers of HIV carriers. Furthermore, IDUs
frequently acquire HCV before HIV infection [12,13]. Conse-
quently, there is an interest in assessment of the natural history
of HCV infection and the risk of progressing ﬁbrosis in HIV nega-
tive IDUs.
In the present issue of the journal, Dr. Kielland and co-workers
from Norway evaluated the risk of developing hepatic ﬁbrosis
over a long follow-up of up to 35 years in injecting IDUs infected
with HCV, presumably being HIV negative [14]. This report is in
fact an extension of a recent publication by the same authors
entitled ‘‘All-cause and liver-related mortality in hepatitis C
infected drug users followed for 33 years: A controlled study’’
[15]. The study population consisted originally of 523 anti-HCV
positive IDUs admitted for treatment over a period of 15 years
(1970–1984) to the National Clinic for Drug Abuse in Norway.
The study cohort was ofﬁcially established in 1991 and conse-
quently, some of the data (i.e., causes of death) were collected
retrospectively and others prospectively. At time of analysis in
2008, 220/523 patients died. Liver biopsies obtained at autopsy
and serum for HCV-RNA testing were available for analysis for
approximately one ﬁfth of the original cohort, namely in 102/
220 patients. For most of the patients, age of HCV acquisition
was deducted from time of ﬁrst IV injection. Three sections of
each tissue sample were evaluated by two independent patholo-
gists and the Metavir score was used for determination of the
stage of ﬁbrosis while the degree of inﬂammation and autolysis
was assessed by a four point scale. Of the study cohort of 102
patients, the mean age at autopsy was 37.3 years; 75% were
males, of whom 60% were HCV-RNA positive as determined by
an in-house PCR assay (lower detection limit 100 IU/ml). The
mean observation time from HCV exposure to death was
16.9 years.
One important observation of this study suggest that death
from liver disease in IDUs in Norway, presumably being HIV neg-
ative, is a relatively rare event observed in only 4.9% of HCV-RNA
positive patients during the study period, as compared to 0% in
HCV-RNA negative subjects. Furthermore, F3/F4 ﬁbrosis was
observed in only 16% of HCV-RNA positive chronic HCV patients14 vol. 60 j 239–240
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and compared to 2% in those who apparently cleared HCV and
were HCV-RNA negative. The 16% rate of advanced ﬁbrosis and
only 8% of cirrhosis observed in the study population of 102
autopsied patients is relatively low compared to early reports
on the natural history of chronic HCV infection. It is however sim-
ilar to the ﬁgure quoted by Thein et al. who conducted a meta-
analysis of 111 studies on the natural history of HCV infection
in 33121 HCV patients and modelled the risk of transition to cir-
rhosis [16]. In this meta-analysis, stage-speciﬁc transition proba-
bilities (which are non-linear) were: F0 to F1 0.117; F1 to F2
0.085; F2 to F3 0.120; and F3 to F4 0.116. As also observed previ-
ously in non-IDU patients infected with HCV, extent of ﬁbrosis
was proportional to duration of exposure to HCV (and presum-
ably to viremia), being lower than F3 in subjects with chronic
hepatitis C who died up to 15 years after HCV exposure. In con-
trast, F3/F4 ﬁbrosis was identiﬁed in 35% of HCV-RNA positive
patients who died >25 years post exposure. Most importantly,
the availability of relatively large liver tissue samples obtained
at autopsy contributed indeed to the accuracy of scoring the
degree of ﬁbrosis and avoiding sampling error, which may occur
using conventional needle liver biopsies. Cumulative survival of
HCV-RNA negative patients was indeed better as compared to
the viremic cohort. However, the majority of patients in the
cohort who underwent an autopsy died from drug related causes
such as opiate intoxication, suicide and accidents, and not from
liver disease [15]. Thus almost two thirds of viremic subjects
who were autopsied more than 20 years after HCV exposure
had practically no or minimal hepatic ﬁbrosis. The results of this
study should have been reassuring and may possibly have an
impact on the timing and priority of when and if to treat chronic
HCV infection in HIV negative subjects in this very difﬁcult pop-
ulation, which is often non-compliant. Thus, delaying therapeutic
intervention would enable a chance for longer rehabilitation and
future access to the more potent anti-viral agents, which are now
in the pipe line. However, the study has a number of technical
and methodological limitations, which require further evaluation
and conﬁrmation before drawing deﬁnite conclusions. These
include among others, the relatively small number of IDUs out
of the total who underwent histologic evaluation, the limited
sensitivity of the HCV-RNA assay used, and the lack of genotyp-
ing, which may have an impact on response to treatment and
prognosis. Furthermore, the anti-HCV positive/HCV RNA negative
control group is presumed to have cleared HCV infection. This
may indeed have been the case but conformation using a radio
– immuno blotting assay (RIBA) would have strengthened this
assumption. It is indeed unfortunate that the investigators were
unable to test the sera for HIV infection. There was only one case
of HIV infection in the study cohort, which was not screened sys-
tematically for HIV. The authors hypothesize that HIV infection
rates are relatively low in Scandinavia and provide a European
reference [8] to support this statement quoting a 3.2% prevalence
of HIV in 2006 among IDUs in Norway. However, in the absence
of HIV testing in the described cohort of IDUs in general and espe-
cially in those with advanced hepatic ﬁbrosis in particular, this
assessment remains at best an assumption and consequently
casts some doubt on the robustness of the conclusions regarding
the natural history of HCV infection in this HIV negative IDUs240 Journal of Hepatology 201cohort. Yet, regardless of these limitations and provided that
these patients were indeed HIV negative, the study results may
be representative for large groups of HCV+/HIV IDU patients
who are future candidates for anti-viral therapy during the ﬁrst
two decades of HCV infection with a favourable prognosis con-
cerning their liver disease.Conﬂict of interest
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